BioSpace News Archive

Applied Health Analytics, provider of analytics, technology and services to hospitals and health systems that support population health management, has released an update to its bMetrix™ Biometric Screening application to include vaccine injection management, member communication and reporting capabilities for COVID-19 vaccinations

- DARPA to fund innovative public-private partnership between INOVIO, The Wistar Institute, AstraZeneca, the University of Pennsylvania and Indiana University - $37.6 million grant from DARPA will leverage AstraZeneca’s monoclonal antibody and INOVIO’s DNA-encoded monoclonal antibody (dMAb®) technologies in the fight against COVID-19

Sensorion announces that Sonova Holding AG, a leading provider of hearing solutions, will acquire a 3.7% ownership stake in Sensorion by way of subscription to a reserved share capital increase for total gross proceeds of €5 million.

Within the global healthcare ecosystem, concerns pertaining to the use of radiation and diagnostic imaging tests have led to a considerable rise in the research and development expenditure.

The notable rise in the demand for hereditary genetic testing over the past few years is one of the major factors that is expected to fuel the growth of the global genetic analysis services market in the upcoming decade.

Bone-regeneration techniques, either with autografts or allografts, represent a challenge for reconstructive surgery.

Audiological devices are amplifiers that are utilized as a part of the conclusion and treatment of hearing misfortune and adjust issue.

An apheresis machine comprises of a gadget or device which gathers blood removed from the body of the donor and separates it into the diverse components, for instance, platelets, plasma, platelets, red and white platelets.

Audacious Inquiry (Ai), an industry leader in connected care, and Surescripts, the nation’s leading health information network, are combining forces to improve patient care management during declared disasters by integrating patient medication history data into Ai’s PULSE Enterprise, a platform that allows providers to access medical information for patients in times of emergency.

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today reported top-line results from a U.S. Phase 2 randomized, double-blind, placebo-controlled trial of ANAVEX®2-73